Cargando…

Evaluation of Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant Era

BACKGROUND: Monoclonal antibody (mAb) treatment is associated with decreased risk of hospitalization and death in high-risk outpatients with mild to moderate coronavirus disease 2019 (COVID-19) caused by early severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Bebtelovimab exhibi...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCreary, Erin K, Kip, Kevin E, Collins, Kevin, Minnier, Tami E, Snyder, Graham M, Steiner, Ashley, Meyers, Russell, Borneman, Tina, Adam, Michelle, Thurau, Lauren, Yealy, Donald M, Huang, David T, Bariola, J Ryan, Schmidhofer, Mark, Wadas, Richard J, Angus, Derek C, Kip, Paula L, Marroquin, Oscar C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619560/ https://www.ncbi.nlm.nih.gov/pubmed/36324319 http://dx.doi.org/10.1093/ofid/ofac517

Ejemplares similares

Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
por: Bariola, J Ryan, et al.
Publicado: (2021)

Emergency department implementation of monoclonal antibody infusion for the treatment of coronavirus disease 2019: A template for rapid deployment
por: Woltemate, Thomas J., et al.
Publicado: (2021)

Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19
por: McCreary, Erin K., et al.
Publicado: (2022)

A learning health system approach to the COVID‐19 pandemic: System‐wide changes in clinical practice and 30‐day mortality among hospitalized patients
por: McCreary, Erin K., et al.
Publicado: (2022)

Establishing a Distribution Network for COVID-19 Monoclonal Antibody Therapy Across a Large Health System During a Global Pandemic
por: Bariola, J Ryan, et al.
Publicado: (2021)

The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization
por: Huang, David T., et al.
Publicado: (2021)

Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days
por: McCreary, Erin K., et al.
Publicado: (2022)

Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch
por: Razonable, Raymund R, et al.
Publicado: (2022)

470. Clinical Effectiveness of The Monoclonal Antibody Combination Tixagevimab-Cilgavimab (T/C) as Pre-Exposure Prophylaxis (PReP) of COVID-19 among Patients (pts) with Moderate to Severe Immunocompromised (IC) Conditions across a Large U.S. Healthcare System: A Propensity Score-Matched Retrospective Cohort Study
por: Haidar, Ghady, et al.
Publicado: (2023)

The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial
por: McCreary, Erin K., et al.
Publicado: (2022)

Impact of Clinical Decision Support System Implementation at a Community Hospital With an Existing Tele-Antimicrobial Stewardship Program
por: Khadem, Tina M, et al.
Publicado: (2022)

COVID-19 contagious health care personnel 5-day early return-to-work program
por: Wagester, Suzanne, et al.
Publicado: (2023)

Healthcare personnel early return-to-work program after higher-risk SARS-CoV-2 exposure: A learning health system quality improvement project
por: Ruscetti, Amy, et al.
Publicado: (2022)

Deep Mutational Scanning to Predict Escape from Bebtelovimab in SARS-CoV-2 Omicron Subvariants
por: Alcantara, Mellissa C., et al.
Publicado: (2023)

Bebtelovimab-Induced Bradycardia Leading to Cardiac Arrest
por: Gearges, Christina, et al.
Publicado: (2022)

Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5
por: Molina, Kyle C., et al.
Publicado: (2023)

A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab
por: Hentzien, Maxime, et al.
Publicado: (2022)

Development of a Centralized Antimicrobial Stewardship Program Across a Diverse Health System and Early Antimicrobial Usage Trends
por: Khadem, Tina M, et al.
Publicado: (2022)

Preprocedural SARS-CoV-2 Testing to Sustain Medically Needed Health Care Delivery During the COVID-19 Pandemic: A Prospective Observational Study
por: Haidar, Ghady, et al.
Publicado: (2021)

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
por: Westendorf, Kathryn, et al.
Publicado: (2022)

Association of COVID-19 Stay-at-Home Orders With 1-Year Weight Changes
por: Wing, Rena R., et al.
Publicado: (2022)

Changes in body weight and glycemic control in association with COVID-19 Shutdown among 23,000 adults with type 2 diabetes
por: Panza, Emily, et al.
Publicado: (2023)

Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS)
por: Haidar, Ghady, et al.
Publicado: (2022)

Effectiveness of COVID-19 Vaccines Over Time Prior to Omicron Emergence in Ontario, Canada: Test-Negative Design Study
por: Chung, Hannah, et al.
Publicado: (2022)

Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic
por: Nichols, Russell M, et al.
Publicado: (2022)

The effect of bebtelovimab on clinical outcomes in patients with COVID-19: A meta-analysis
por: Luo, Jie, et al.
Publicado: (2023)

Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System
por: Dryden-Peterson, Scott, et al.
Publicado: (2022)

Multicenter Cohort of Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments
por: McCreary, Erin K, et al.
Publicado: (2019)

Outcomes of Bebtelovimab Therapy in Patients With Solid Organ Transplantation With Mild and Moderate COVID-19
por: Kapur, Rohan, et al.
Publicado: (2023)

Comparison of Indirect Fungal Diagnostic Tests in Patients With Proven Histoplasmosis
por: Krishnan, Gayathri, et al.
Publicado: (2022)

Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization
por: Morris, C Paul, et al.
Publicado: (2022)

Assessment of the effectiveness of ultraviolet-C disinfection on transmission of hospital-acquired pathogens from prior room occupants
por: Hodges, Jacob C., et al.
Publicado: (2022)

Population Immunity to Pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Variants in US States and Counties Through 1 December 2021
por: Klaassen, Fayette, et al.
Publicado: (2022)

951. Implementation and Rapid Uptake of an Antimicrobial Stewardship Clinical Decision Support System Across 19 UPMC Hospitals
por: Ryan Bariola, J, et al.
Publicado: (2022)

COVID-19 Outcomes in Solid Organ Transplant Recipients Who Received Tixagevimab-cilgavimab Prophylaxis and/or Bebtelovimab Treatment in a Nurse-driven Monoclonal Antibody Program During the Omicron Surge
por: Cochran, Willa, et al.
Publicado: (2022)

SARS-CoV-2 neutralizing antibody bebtelovimab – a systematic scoping review and meta-analysis
por: Liew, Mabel Nyit Yi, et al.
Publicado: (2023)

Clindamycin Plus Vancomycin Versus Linezolid for Treatment of Necrotizing Soft Tissue Infection
por: Dorazio, Joshua, et al.
Publicado: (2023)

Stewardship-Guided T2Candida Testing Shortens Time to Antifungal Treatment and Reduces Antifungal Usage Among Medical Intensive Care Unit Patients With Septic Shock
por: O’Donnell, Matthew, et al.
Publicado: (2023)

Clinical Characteristics and Outcomes of Immunocompromised Patients With Coronavirus Disease 2019 Caused by the Omicron Variant: A Prospective, Observational Study
por: Malahe, S Reshwan K, et al.
Publicado: (2022)

A TALE OF TWO CASE STUDIES: ACCELERATED RESOLUTION THERAPY FOR COMPLICATED GRIEF IN OLDER ADULTS
por: Buck, Harleah G, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_viiaf7gmr77nnlpba3ntnem40h